ClinicalTrials.gg
CompletedNCT01235689CALMUpdated Jan 16, 2018Results posted

Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease

A Phase 3 interventional study of Adalimumab and Prednisone in Crohn's Disease, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-01-16.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
10th of 42
252 · median 143
Started
2011
the only one that year
Phase 3
22 of 42
none open now
Registered
18th of 42
by date
Lead sponsor
2 of 42
AbbVie (prior sponsor, Abbott)

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 10th largest by enrollment, is the only one that started in 2011, is one of 22 in phase 3, and was the 18th registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

The primary objective of this study was to demonstrate that tight control of disease activity, using stringent criteria based on Crohn's disease activity Index (CDAI), biomarkers (high sensitivity C-reactive protein [hs-CRP] and fecal calprotectin), and corticosteroid use, improves the rate of mucosal healing 48 weeks after randomization compared with management using less stringent criteria based only on CDAI and corticosteroid use.

Read the detailed description

The study included a 1- to 3-week screening period, up to 8 weeks of prednisone run-in treatment, a 48-week post-randomization treatment period, and a 70 day follow-up phone call or clinic visit, for a total duration of up to 69 weeks.

Participants who met entry criteria were enrolled and initiated an oral prednisone regimen at Baseline (Week 0). At the first key visit, participants were randomized into 1 of 2 groups (Tight Control group or Clinically Driven group), with stratification according to screening smoking status, weight, and disease duration.

The first key visit was the randomization visit; subsequent key visits occurred every 12 weeks following the first key visit. Randomization normally took place 9 weeks after Baseline. However, participants who fulfilled the early randomization criteria may have been randomized as early as the Baseline (Week 0) visit. Therapeutic option changes, if appropriate, occurred at key visits based on results from previous success criteria visits.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ileal, colonic (including rectal), or ileocolonic Crohn's disease (CD) confirmed using imaging technology or endoscopy not more than 6 years prior to Baseline.
  • CDAI score of greater than or equal to 220 and less than or equal to 450 at the Baseline visit in participants not receiving prednisone or equivalent at Baseline. CDAI score of greater than or equal to 200 and less than or equal to 450 at the Baseline visit if the participant is receiving prednisone less than or equal to 20 mg or equivalent for at least 7 days before Baseline. CDAI score of greater than 150 and less than or equal to 450 at the Baseline visit if the participant is receiving prednisone higher than 20 mg or equivalent for greater than or equal to 7 days before Baseline
  • Participant or his/her legal representative have voluntarily signed and dated an approved by and compliant with the requirements of this study protocol which has been approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
  • Adequate cardiac, renal and hepatic function as determined by the Principal Investigator and demonstrated by Screening laboratory evaluations, questionnaires and physical examination results that do not indicate an abnormal clinical condition which would place the participant at undue risk and thus preclude participation in the study.
  • Participant must be able to self-inject and orally administer study medication or have a designee or Healthcare Professional who can assist

Exclusion criteria

Exclusion Criteria:

  • Previous or current biologic use for Crohn's disease or participation in a biologic study
  • Previous or current use of immunomodulators (e.g., methotrexate, azathioprine, 6-mercaptopurine, JAK inhibitor, alpha-integrin) for Crohn's disease or participation in a Crohn's disease study with immunomodulator(s). Current use of immunomodulators for non-Crohn's disease at Baseline.
  • Greater than two previous courses of (systemic corticosteroid) or budesonide) for Crohn's Disease. A course is defined as 1) total duration for burst and taper ≥ 4 weeks and 2) prednisone or equivalent ≥ 40 mg (or budesonide ≥ 9 mg) for at least 2 weeks.
  • Participants with a poorly controlled medical condition such as: uncontrolled diabetes with documented history of recurrent infections, unstable ischemic heart disease, moderate to severe congestive heart failure ( [NYHA] class III or IV), recent cerebrovascular accident and any other condition which, in the opinion of the Investigator or the sponsor, would put the participant at risk by participation in the protocol
  • Participants with positive C. difficile stool assay at Screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    Tight Control Management

    Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI), high sensitivity C-reactive protein (hs-CRP), fecal calprotectin, and corticosteroid use. Participants received customized therapy that could include prednisone, adalimumab, and azathioprine. Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab. Therapy was escalated according to pre-specified tight control criteria: At Key Visit 1 the success criteria were CDAI \< 150, hs-CRP, \< 5 mg/L, fecal calprotectin \< 250 μg/g, and absence of prednisone use. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria were CDAI \< 150, hs-CRP \< 5 mg/L, fecal calprotectin \< 250 μg/g, and absence of prednisone during the preceding week.

    Biological: Adalimumab · Drug: Prednisone · Drug: Azathioprine

  • Active comparator
    Clinically Driven Management

    Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI) and corticosteroid use. Participants received customized therapy that could include prednisone, adalimumab, and azathioprine. Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab. Therapy was escalated according to pre-specified failure criteria using less stringent criteria: At Key Visit 1 the criteria for management of disease activity were a CDAI decrease ≥ 70 (CR-70) compared to Baseline or CDAI \< 200 at 1 week prior to the visit. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria for a change in treatment were a CDAI decrease of ≥ 100 (CR-100) compared to Baseline or CDAI \< 200, and absence of prednisone during the preceding week.

    Biological: Adalimumab · Drug: Prednisone · Drug: Azathioprine

Interventions

  • BiologicalAdalimumab

    If adalimumab was initiated, it was administered subcutaneously as a 160 mg induction dose the first week, followed by 80 mg 2 weeks later, followed by 40 mg every other week as a maintenance dose. The dose of adalimumab was increased from 40 mg eow to 40 mg every week in participants with an inadequate response and de-escalated to 40 mg eow in participants who met success criteria.

    Also known as: ABT-D2E7, Humira

  • The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.

  • Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Mucosal Healing and No Deep Ulcerations

    Percentage of participants with mucosal healing (defined as Crohn's disease endoscopy Index of severity \[CDEIS\] \< 4) and no deep ulcerations on ileocolonoscopy (defined as the absence of all deep ulcerations in all segments explored in CDEIS) at 48 weeks after randomization (48 weeks after the 1st Key visit). The ileocolonoscopies were evaluated by the site. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Participants with missing data 48 weeks after Randomization were counted as non-responders.

    Time frame: 48 weeks after Randomization

Secondary outcomes

  1. Percentage of Participants in Deep Remission 48 Weeks After Randomization

    Deep remission was defined as CDAI \< 150, discontinuation from steroids for at least 8 weeks, absence of draining fistula, CDEIS \< 4 and no deep ulcerations. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity. Participants with missing data 48 weeks after randomization were counted as non-responders.

    Time frame: 48 weeks after Randomization

  2. Percentage of Participants in Biologic Remission 48 Weeks After Randomization

    Biologic remission was defined as high sensitivity C-reactive protein (hs-CRP) \< 5 mg/L, fecal Calprotectin \< 250 μg/g, and CDEIS \< 4 at 48 weeks after randomization. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity. Participants with missing values 48 weeks after Randomization were counted as non-responders.

    Time frame: 48 weeks after Randomization

  3. Percentage of Participants With Mucosal Healing 48 Weeks After Randomization

    Percentage of participants with mucosal healing (defined as a CDEIS \< 4) at 48 weeks after randomization (48 weeks after the 1st Key visit). The ileocolonoscopies were evaluated by the site. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity. Participants with missing values 48 weeks after Randomization were counted as non-responders.

    Time frame: 48 weeks after Randomization

  4. Percentage of Participants With Mucosal Healing and CDEIS < 4 in Every Segment 48 Weeks After Randomization

    Percentage of participants with mucosal healing (defined as CDEIS \< 4) and CDEIS \< 4 in every segment on ileocolonoscopy at 48 weeks after randomization. The ileocolonoscopies were evaluated by the site. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity. Participants with missing values 48 weeks after randomization were counted as non-responders.

    Time frame: 48 weeks after Randomization

  5. Percentage of Participants With Complete Mucosal Healing 48 Weeks After Randomization

    Complete mucosal healing was defined as CDEIS = 0. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity. Participants with missing values 48 weeks after randomization were counted as non-responders.

    Time frame: 48 weeks after Randomization

  6. Percentage of Participants With Endoscopic Response 48 Weeks After Randomization

    Endoscopic response was defined as a decrease CDEIS \> 5 points. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity. Participants with missing values 48 weeks after Randomization were counted as non-responders.

    Time frame: 48 weeks after Randomization

  7. Change From Baseline in CDEIS at 48 Weeks After Randomization

    CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. A negative change from Baseline indicates improvement.

    Time frame: Baseline and 48 weeks after Randomization

  8. Change From Baseline in CDAI Over Time

    The Crohn's Disease Activity Index (CDAI) is a research tool used to quantify the symptoms of patients with Crohn's disease. Participants were asked to record the frequency of stools, abdominal pain and general well-being on a daily basis. In addition to the diary data, the investigator assessed the following for the calculation of CDAI: presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. The CDAI is the sum of the products of each item multiplied by a weighting factor and generally ranges from 0 up to 600, where remission of Crohn's disease is defined as CDAI \< 150, and severe disease is defined as CDAI \> 450. A negative change from Baseline indicates improvement.

    Time frame: Baseline and 4 and 8 weeks during the prednisone run-in, and 2, 6, 11, 14, 18, 23, 26, 30, 35, 38, 42, and 48 weeks after Randomization.

  9. Time to Crohn's Disease Flare

    Time to Crohn's disease flare, where flare is defined as an increase in CDAI ≥ 70 points compared to Week 8 or Early Randomization CDAI, and a CDAI \> 220.

    Time frame: From Randomization to 48 weeks after Randomization

  10. Time to Clinical Remission

    Clinical remission was defined as CDAI \< 150. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI scores generally range from 0 to 600 where higher scores indicate more severe disease.

    Time frame: From Randomization through 48 weeks after Randomization

  11. Time to Steroid-free Remission

    Steroid-free remission was defined as CDAI \< 150 and discontinuation from steroids for at least 8 weeks. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease.

    Time frame: From Randomization through 48 weeks after Randomization

  12. Percentage of Participants in Clinical Remission Over Time

    Clinical remission was defined as CDAI \< 150. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. Participants with missing data at each time point were counted as non-responders.

    Time frame: Baseline and 4 and 8 weeks during the prednisone run-in, and 2, 6, 11, 14, 18, 23, 26, 30, 35, 38, 42, and 48 weeks after Randomization.

  13. Percentage of Participants in Steroid-free Remission Over Time

    Steroid-free remission was defined as CDAI \< 150 and discontinuation from steroids for at least 8 weeks. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. Participants with missing data at each time point were counted as non-responders.

    Time frame: 11, 14, 18, 23, 26, 30, 35, 38, 42, and 48 weeks after Randomization.

  14. Time to All-cause Hospitalization

    Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic.

    Time frame: From Randomization through 48 weeks after Randomization

  15. Time to Crohn's Disease-related Hospitalization or Hospitalization Due to Adverse Event Relating to Study Medication

    Crohn's disease-related hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic for reasons related to Crohn's disease (CD). Hospitalization for adverse events relating to study medication, i.e., prednisone, azathioprine or adalimumab, were according to Investigator's clinical judgment.

    Time frame: From Randomization through 48 weeks after Randomization

  16. Number of Major Crohn's Disease-related Surgeries After Randomization

    Major Crohn's disease-related intra-abdominal surgery included: * bowel resection * ostomy * by-pass * strictureplasty * drainage of abdominal or pelvic abscess (surgical drainage or percutaneous drainage by interventional radiology). The following were excluded: * debridement * exploration laparotomy * abdominal surgery for other reason * perineal related surgery * abscess drainage * placement of setons * fistulotomy * Total parental nutrition (TPN) use

    Time frame: From Randomization through 48 weeks after Randomization

  17. Number of Crohn's Disease-related Hospitalizations After Randomization

    Any hospitalization with an overnight stay in hospital/clinic related to Crohn's disease.

    Time frame: From Randomization through 48 weeks after Randomization

  18. Number of All-cause Hospitalizations After Randomization

    Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic.

    Time frame: From Randomization through 48 weeks after Randomization

  19. Total Length of Stay in Hospital for All-cause Hospitalizations

    Time frame: From Randomization through 48 weeks after Randomization

  20. Total Length of Stay in Hospital for Crohn's Disease-related Hospitalizations

    Time frame: From Randomization through 48 weeks after Randomization

  21. Number of Crohn's Disease-related Surgical Procedures After Randomization

    The total number of CD-related surgical procedures included major CD-related surgery, debridement, perineal related surgery - abscess drainage, seton placement, fistulotomy, and TPN.

    Time frame: From Randomization through 48 weeks after Randomization

  22. Time to Crohn's Disease-related Hospitalization Due to Emergency

    Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic. Hospitalization due to emergency was defined as a hospitalization admitted through the emergency department.

    Time frame: From Randomization through 48 weeks after Randomization

  23. Number of Crohn's Disease-related Hospitalizations Due to Emergency

    Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic. Hospitalization due to emergency was defined as a hospitalization admitted through the emergency department.

    Time frame: From Randomization through 48 weeks after Randomization

  24. Change in Crohn's Disease Behavior According to Montreal Classification

    Participants' Crohn's Disease was classified according to the Montreal Classification which classifies CD according to its predominant phenotypic elements (age at diagnosis, location, and disease behavior) based on the results of clinical examination and endoscopy. Disease behavior was classified according to the following: B1 = non-stricturing, non-penetrating; B2 = structuring; B3 = penetrating; P = perianal disease modifier. The change in Montreal Classification is presented in three categories: no change, deterioration, and improvement. Deterioration was defined as an increase in behavior index between 1 and 3, or development of perianal disease. Participants with missing data at Week 48 were classified as deterioration.

    Time frame: From Baseline to 48 weeks after Randomization

  25. Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Over Time

    High sensitivity C-reactive protein was analyzed by a central laboratory.

    Time frame: Baseline and 8 weeks during the prednisone run-in, and 11, 23, 35, and 48 weeks after Randomization.

  26. Change in Fecal Calprotectin From Baseline to 48 Weeks After Randomization

    Stool samples were analyzed by a central laboratory for fecal calprotectin qualitative measurement (\< 250 or ≥ 250 μg/g). Results are reported for participants in each category at Baseline and 48 weeks after Randomization. Participants with missing data 48 weeks after Randomization were counted as having fecal calprotectin ≥ 250µg/g.

    Time frame: Baseline and 48 weeks after Randomization

  27. Total Dose of Prednisone

    The total dose of prednisone each participant received during both the run-in phase and post-randomization treatment phase.

    Time frame: From Baseline through 48 weeks after Randomization

  28. Change From Baseline in Quality of Life in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

    The IBDQ measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease, feeling in general, and mood. Each question is answered on a scale from 1 (all of the time) to 7 ( none of the time); the total score ranges from 7 (worst) to 224 (best). A positive change from baseline indicates improvement.

    Time frame: Baseline and 48 weeks after Randomization

  29. Change From Baseline in Work Productivity Activity Index - Crohn's Disease (WPAI:CD)

    The WPAI:CD questionnaire was used to assess impairments in both paid work and unpaid work due to symptoms of Crohn's Disease. The self-administered questionnaire consisted of 6 questions. Work time missed was defined as the percentage of time absent from work due to Crohn's disease in the past week. Impairment while working is the participant's assessment of the degree to which Crohn's disease affected productivity while working in the past 7 days. Total work productivity impairment takes into account both hours missed due to Crohn's disease symptoms and the patient's assessment of the degree to which Crohn's disease affected their productivity while working. Total activity impairment is the percent impairment of non-work related activities due to Crohn's disease. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.

    Time frame: Baseline and 48 weeks after Randomization

  30. Change From Baseline in Patient Health Questionnaire - 9 (PHQ9)

    The PHQ-9 is a 9-item questionnaire for assessing the severity of depression. Each question is answered on a scale from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 27, where higher scores indicate more severe depression. A negative change from Baseline score indicates improvement.

    Time frame: Baseline and 48 weeks after Randomization

  31. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score

    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, from 0 (not at all) to 4 (very much). The FACIT-Fatigue score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from Baseline score indicates an improvement. .

    Time frame: Baseline and 48 weeks after Randomization

  32. Change From Baseline in Short-Form 36 (SF-36) Physical Component Summary and Mental Component Summary Scores

    The Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2 is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary (PCS) score summarizes the subscales physical functioning, role-physical, bodily pain, and general health. The mental component summary (MCS) score summarizes the subscales vitality, social functioning, role-emotional, and mental health. Each score ranges from 0 to 100 where higher scores indicate a better quality of life. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and 48 weeks after Randomization

07

Results

Posted Dec 7, 2017

Participant flow

This study was conducted at 59 sites in Canada, European Union, Israel, Japan, Russia, South Africa, Switzerland, Turkey, and the Ukraine. The study included a screening period, up to 8 weeks of prednisone run-in treatment, a 48-week post-randomization treatment period, and a 70 day follow-up phone call or clinic visit.

Participant flow — Overall Study
MilestoneClinically Driven ManagementTight Control Management
Started122122
Early randomized (baseline to week 9)6369
Randomized at week 95953
Completed9390
Not completed2932
Withdrew: Adverse event1216
Withdrew: Lack of efficacy125
Withdrew: Withdrawal by subject34
Withdrew: Lost to follow-up12
Withdrew: Miscellaneous15

Outcome measures

PrimaryPercentage of Participants With Mucosal Healing and No Deep Ulcerations

Percentage of participants with mucosal healing (defined as Crohn's disease endoscopy Index of severity \[CDEIS\] \< 4) and no deep ulcerations on ileocolonoscopy (defined as the absence of all deep ulcerations in all segments explored in CDEIS) at 48 weeks after randomization (48 weeks after the 1st Key visit). The ileocolonoscopies were evaluated by the site. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Participants with missing data 48 weeks after Randomization were counted as non-responders.

Time frame:
48 weeks after Randomization
Reported as:
Number · percentage of participants
Percentage of Participants With Mucosal Healing and No Deep Ulcerations
percentage of participantsClinically Driven ManagementTight Control Management
Percentage of Participants With Mucosal Healing and No Deep Ulcerations30.345.9
Statistical analysis
  • Clinically Driven Management vs Tight Control Management · Cochran-Mantel-Haenszel · p = 0.010Cochran-Mantel-Haenszel (CMH) test stratified by Screening smoking status (yes or no) and weight (\< 70 kg or ≥ 70 kg).
SecondaryPercentage of Participants in Deep Remission 48 Weeks After Randomization

Deep remission was defined as CDAI \< 150, discontinuation from steroids for at least 8 weeks, absence of draining fistula, CDEIS \< 4 and no deep ulcerations. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity. Participants with missing data 48 weeks after randomization were counted as non-responders.

Time frame:
48 weeks after Randomization
Reported as:
Number · percentage of participants
Percentage of Participants in Deep Remission 48 Weeks After Randomization
percentage of participantsClinically Driven ManagementTight Control Management
Percentage of Participants in Deep Remission 48 Weeks After Randomization23.036.9
Statistical analysis
  • Clinically Driven Management vs Tight Control Management · Cochran-Mantel-Haenszel · p = 0.014CMH test stratified by screening smoking status (yes or no) and weight (\< 70 kg, ≥ 70 kg).
SecondaryPercentage of Participants in Biologic Remission 48 Weeks After Randomization

Biologic remission was defined as high sensitivity C-reactive protein (hs-CRP) \< 5 mg/L, fecal Calprotectin \< 250 μg/g, and CDEIS \< 4 at 48 weeks after randomization. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity. Participants with missing values 48 weeks after Randomization were counted as non-responders.

Time frame:
48 weeks after Randomization
Reported as:
Number · percentage of participants
Percentage of Participants in Biologic Remission 48 Weeks After Randomization
percentage of participantsClinically Driven ManagementTight Control Management
Percentage of Participants in Biologic Remission 48 Weeks After Randomization15.629.5
Statistical analysis
  • Clinically Driven Management vs Tight Control Management · Cochran-Mantel-Haenszel · p = 0.006CMH test stratified by screening smoking status (yes or no) and weight (\< 70 kg, ≥ 70 kg).
SecondaryPercentage of Participants With Mucosal Healing 48 Weeks After Randomization

Percentage of participants with mucosal healing (defined as a CDEIS \< 4) at 48 weeks after randomization (48 weeks after the 1st Key visit). The ileocolonoscopies were evaluated by the site. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity. Participants with missing values 48 weeks after Randomization were counted as non-responders.

Time frame:
48 weeks after Randomization
Reported as:
Number · percentage of participants
Percentage of Participants With Mucosal Healing 48 Weeks After Randomization
percentage of participantsClinically Driven ManagementTight Control Management
Percentage of Participants With Mucosal Healing 48 Weeks After Randomization30.345.9
Statistical analysis
  • Clinically Driven Management vs Tight Control Management · Cochran-Mantel-Haenszel · p = 0.010CMH test stratified by screening smoking status (yes or no) and weight (\< 70 kg, ≥ 70 kg).
SecondaryPercentage of Participants With Mucosal Healing and CDEIS < 4 in Every Segment 48 Weeks After Randomization

Percentage of participants with mucosal healing (defined as CDEIS \< 4) and CDEIS \< 4 in every segment on ileocolonoscopy at 48 weeks after randomization. The ileocolonoscopies were evaluated by the site. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity. Participants with missing values 48 weeks after randomization were counted as non-responders.

Time frame:
48 weeks after Randomization
Reported as:
Number · percentage of participants
Percentage of Participants With Mucosal Healing and CDEIS < 4 in Every Segment 48 Weeks After Randomization
percentage of participantsClinically Driven ManagementTight Control Management
Percentage of Participants With Mucosal Healing and CDEIS < 4 in Every Segment 48 Weeks After Randomization23.829.5
Statistical analysis
  • Clinically Driven Management vs Tight Control Management · Cochran-Mantel-Haenszel · p = 0.299CMH test stratified by screening smoking status (yes or no) and weight (\< 70 kg, ≥ 70 kg).
SecondaryPercentage of Participants With Complete Mucosal Healing 48 Weeks After Randomization

Complete mucosal healing was defined as CDEIS = 0. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity. Participants with missing values 48 weeks after randomization were counted as non-responders.

Time frame:
48 weeks after Randomization
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Mucosal Healing 48 Weeks After Randomization
percentage of participantsClinically Driven ManagementTight Control Management
Percentage of Participants With Complete Mucosal Healing 48 Weeks After Randomization16.418.0
Statistical analysis
  • Clinically Driven Management vs Tight Control Management · Cochran-Mantel-Haenszel · p = 0.728CMH test stratified by screening smoking status (yes or no) and weight (\< 70 kg, ≥ 70 kg).
SecondaryPercentage of Participants With Endoscopic Response 48 Weeks After Randomization

Endoscopic response was defined as a decrease CDEIS \> 5 points. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity. Participants with missing values 48 weeks after Randomization were counted as non-responders.

Time frame:
48 weeks after Randomization
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Response 48 Weeks After Randomization
percentage of participantsClinically Driven ManagementTight Control Management
Percentage of Participants With Endoscopic Response 48 Weeks After Randomization40.250.8
Statistical analysis
  • Clinically Driven Management vs Tight Control Management · Cochran-Mantel-Haenszel · p = 0.067CMH test stratified by screening smoking status (yes or no) and weight (\< 70 kg, ≥ 70 kg).
SecondaryChange From Baseline in CDEIS at 48 Weeks After Randomization

CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. A negative change from Baseline indicates improvement.

Time frame:
Baseline and 48 weeks after Randomization
Reported as:
Mean · units on a scale
Change From Baseline in CDEIS at 48 Weeks After Randomization
units on a scaleClinically Driven ManagementTight Control Management
Change From Baseline in CDEIS at 48 Weeks After Randomization-6.4 ± 7.69-7.7 ± 7.25
Statistical analysis
  • Clinically Driven Management vs Tight Control Management · ANCOVA · p = 0.116 · Ls mean difference: -1.4 · 95% CI -3.2 to 0.4Model included factors for treatment group, screening smoking status (yes or no), and weight (\< 70 kg, ≥ 70 kg), and Baseline values as covariate.
SecondaryChange From Baseline in CDAI Over Time

The Crohn's Disease Activity Index (CDAI) is a research tool used to quantify the symptoms of patients with Crohn's disease. Participants were asked to record the frequency of stools, abdominal pain and general well-being on a daily basis. In addition to the diary data, the investigator assessed the following for the calculation of CDAI: presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. The CDAI is the sum of the products of each item multiplied by a weighting factor and generally ranges from 0 up to 600, where remission of Crohn's disease is defined as CDAI \< 150, and severe disease is defined as CDAI \> 450. A negative change from Baseline indicates improvement.

Time frame:
Baseline and 4 and 8 weeks during the prednisone run-in, and 2, 6, 11, 14, 18, 23, 26, 30, 35, 38, 42, and 48 weeks after Randomization.
Reported as:
Mean · units on a scale
Change From Baseline in CDAI Over Time
units on a scaleClinically Driven ManagementTight Control Management
Week 4 of Prednisone Run-in-78.3 ± 80.02-90.9 ± 81.53
Week 8 of Prednisone Run-in-64.2 ± 90.48-105.5 ± 88.40
2 Weeks After Randomization-80.2 ± 82.27-110.1 ± 85.06
6 Weeks After Randomization-93.1 ± 100.81-130.8 ± 89.40
11 Weeks After Randomization-103.5 ± 98.65-141.0 ± 97.82
14 Weeks After Randomization-71.1 ± 89.18-101.2 ± 115.90
18 Weeks After Randomization-69.9 ± 78.95-112.0 ± 115.01
23 Weeks After Randomization-143.3 ± 97.83-154.1 ± 101.63
26 Weeks After Randomization-71.8 ± 129.09-135.7 ± 112.43
30 Weeks After Randomization-47.9 ± 143.75-143.8 ± 103.54
35 Weeks After Randomization-140.4 ± 104.83-166.4 ± 93.12
38 Weeks After Randomization-60.8 ± 83.51-132.8 ± 103.15
42 Weeks After Randomization-76.8 ± 78.53-107.4 ± 99.19
48 Weeks After Randomization-146.2 ± 102.87-175.8 ± 97.69
SecondaryTime to Crohn's Disease Flare

Time to Crohn's disease flare, where flare is defined as an increase in CDAI ≥ 70 points compared to Week 8 or Early Randomization CDAI, and a CDAI \> 220.

Time frame:
From Randomization to 48 weeks after Randomization
Reported as:
Median · days
Time to Crohn's Disease Flare
daysClinically Driven ManagementTight Control Management
Time to Crohn's Disease FlareNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Clinically Driven Management vs Tight Control Management · Regression, Cox · p = 0.012 · Cox proportional hazard: 0.442 · 95% CI 0.2 to 0.8
SecondaryTime to Clinical Remission

Clinical remission was defined as CDAI \< 150. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI scores generally range from 0 to 600 where higher scores indicate more severe disease.

Time frame:
From Randomization through 48 weeks after Randomization
Reported as:
Median · days
Time to Clinical Remission
daysClinically Driven ManagementTight Control Management
Time to Clinical Remission78 (28 to 163)43 (15 to 101)
Statistical analysis
  • Clinically Driven Management vs Tight Control Management · Regression, Cox · p = 0.008 · Cox proportional hazard: 1.450 · 95% CI 1.1 to 1.9
SecondaryTime to Steroid-free Remission

Steroid-free remission was defined as CDAI \< 150 and discontinuation from steroids for at least 8 weeks. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease.

Time frame:
From Randomization through 48 weeks after Randomization
Reported as:
Median · days
Time to Steroid-free Remission
daysClinically Driven ManagementTight Control Management
Time to Steroid-free Remission162 (80 to 255)159 (78 to 168)
Statistical analysis
  • Clinically Driven Management vs Tight Control Management · Regression, Cox · p = 0.052 · Cox proportional hazard: 1.337 · 95% CI 1.0 to 1.8
SecondaryPercentage of Participants in Clinical Remission Over Time

Clinical remission was defined as CDAI \< 150. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. Participants with missing data at each time point were counted as non-responders.

Time frame:
Baseline and 4 and 8 weeks during the prednisone run-in, and 2, 6, 11, 14, 18, 23, 26, 30, 35, 38, 42, and 48 weeks after Randomization.
Reported as:
Number · percentage of participants
Percentage of Participants in Clinical Remission Over Time
percentage of participantsClinically Driven ManagementTight Control Management
Week 4 of Prednisone Run-in24.630.3
Week 8 of Prednisone Run-in14.822.1
2 Weeks After Randomization23.841.0
6 Weeks After Randomization32.847.5
11 Weeks After Randomization41.862.3
14 Weeks After Randomization8.26.6
18 Weeks After Randomization9.08.2
23 Weeks After Randomization50.865.6
26 Weeks After Randomization4.120.5
30 Weeks After Randomization3.323.0
35 Weeks After Randomization45.159.8
38 Weeks After Randomization4.19.0
42 Weeks After Randomization4.17.4
48 Weeks After Randomization43.459.8
SecondaryPercentage of Participants in Steroid-free Remission Over Time

Steroid-free remission was defined as CDAI \< 150 and discontinuation from steroids for at least 8 weeks. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. Participants with missing data at each time point were counted as non-responders.

Time frame:
11, 14, 18, 23, 26, 30, 35, 38, 42, and 48 weeks after Randomization.
Reported as:
Number · percentage of participants
Percentage of Participants in Steroid-free Remission Over Time
percentage of participantsClinically Driven ManagementTight Control Management
11 Weeks After Randomization23.839.3
14 Weeks After Randomization4.14.9
18 Weeks After Randomization3.37.4
23 Weeks After Randomization45.163.1
26 Weeks After Randomization2.518.9
30 Weeks After Randomization0.821.3
35 Weeks After Randomization42.659.0
38 Weeks After Randomization4.19.0
42 Weeks After Randomization4.17.4
48 Weeks After Randomization39.359.8
SecondaryTime to All-cause Hospitalization

Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic.

Time frame:
From Randomization through 48 weeks after Randomization
Reported as:
Median · days
Time to All-cause Hospitalization
daysClinically Driven ManagementTight Control Management
Time to All-cause HospitalizationNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Clinically Driven Management vs Tight Control Management · Regression, Cox · p = 0.501 · Cox proportional hazard: 0.823 · 95% CI 0.5 to 1.5
SecondaryTime to Crohn's Disease-related Hospitalization or Hospitalization Due to Adverse Event Relating to Study Medication

Crohn's disease-related hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic for reasons related to Crohn's disease (CD). Hospitalization for adverse events relating to study medication, i.e., prednisone, azathioprine or adalimumab, were according to Investigator's clinical judgment.

Time frame:
From Randomization through 48 weeks after Randomization
Reported as:
Median · days
Time to Crohn's Disease-related Hospitalization or Hospitalization Due to Adverse Event Relating to Study Medication
daysClinically Driven ManagementTight Control Management
Time to Crohn's Disease-related Hospitalization or Hospitalization Due to Adverse Event Relating to Study MedicationNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Clinically Driven Management vs Tight Control Management · Regression, Cox · p = 0.459 · Cox proportional hazard: 0.785 · 95% CI 0.4 to 1.5
SecondaryNumber of Major Crohn's Disease-related Surgeries After Randomization

Major Crohn's disease-related intra-abdominal surgery included: * bowel resection * ostomy * by-pass * strictureplasty * drainage of abdominal or pelvic abscess (surgical drainage or percutaneous drainage by interventional radiology). The following were excluded: * debridement * exploration laparotomy * abdominal surgery for other reason * perineal related surgery * abscess drainage * placement of setons * fistulotomy * Total parental nutrition (TPN) use

Time frame:
From Randomization through 48 weeks after Randomization
Reported as:
Number · surgeries
Number of Major Crohn's Disease-related Surgeries After Randomization
surgeriesClinically Driven ManagementTight Control Management
Number of Major Crohn's Disease-related Surgeries After Randomization36
SecondaryNumber of Crohn's Disease-related Hospitalizations After Randomization

Any hospitalization with an overnight stay in hospital/clinic related to Crohn's disease.

Time frame:
From Randomization through 48 weeks after Randomization
Reported as:
Number · hospitalizations
Number of Crohn's Disease-related Hospitalizations After Randomization
hospitalizationsClinically Driven ManagementTight Control Management
Number of Crohn's Disease-related Hospitalizations After Randomization2914
SecondaryNumber of All-cause Hospitalizations After Randomization

Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic.

Time frame:
From Randomization through 48 weeks after Randomization
Reported as:
Number · hospitalizations
Number of All-cause Hospitalizations After Randomization
hospitalizationsClinically Driven ManagementTight Control Management
Number of All-cause Hospitalizations After Randomization3725
SecondaryTotal Length of Stay in Hospital for All-cause Hospitalizations
Time frame:
From Randomization through 48 weeks after Randomization
Reported as:
Mean · days
Total Length of Stay in Hospital for All-cause Hospitalizations
daysClinically Driven ManagementTight Control Management
Total Length of Stay in Hospital for All-cause Hospitalizations40.2 ± 45.7250.1 ± 85.69
SecondaryTotal Length of Stay in Hospital for Crohn's Disease-related Hospitalizations
Time frame:
From Randomization through 48 weeks after Randomization
Reported as:
Mean · days
Total Length of Stay in Hospital for Crohn's Disease-related Hospitalizations
daysClinically Driven ManagementTight Control Management
Total Length of Stay in Hospital for Crohn's Disease-related Hospitalizations9.8 ± 7.2115.8 ± 20.39
SecondaryNumber of Crohn's Disease-related Surgical Procedures After Randomization

The total number of CD-related surgical procedures included major CD-related surgery, debridement, perineal related surgery - abscess drainage, seton placement, fistulotomy, and TPN.

Time frame:
From Randomization through 48 weeks after Randomization
Reported as:
Number · surgical procedures
Number of Crohn's Disease-related Surgical Procedures After Randomization
surgical proceduresClinically Driven ManagementTight Control Management
Number of Crohn's Disease-related Surgical Procedures After Randomization97
SecondaryTime to Crohn's Disease-related Hospitalization Due to Emergency

Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic. Hospitalization due to emergency was defined as a hospitalization admitted through the emergency department.

Time frame:
From Randomization through 48 weeks after Randomization
Reported as:
Median · days
Time to Crohn's Disease-related Hospitalization Due to Emergency
daysClinically Driven ManagementTight Control Management
Time to Crohn's Disease-related Hospitalization Due to EmergencyNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Clinically Driven Management vs Tight Control Management · Regression, Cox · p = 0.212 · Cox proportional hazard: 0.423 · 95% CI 0.1 to 1.6
SecondaryNumber of Crohn's Disease-related Hospitalizations Due to Emergency

Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic. Hospitalization due to emergency was defined as a hospitalization admitted through the emergency department.

Time frame:
From Randomization through 48 weeks after Randomization
Reported as:
Number · emergency hospitalizations
Number of Crohn's Disease-related Hospitalizations Due to Emergency
emergency hospitalizationsClinically Driven ManagementTight Control Management
Number of Crohn's Disease-related Hospitalizations Due to Emergency114
SecondaryChange in Crohn's Disease Behavior According to Montreal Classification

Participants' Crohn's Disease was classified according to the Montreal Classification which classifies CD according to its predominant phenotypic elements (age at diagnosis, location, and disease behavior) based on the results of clinical examination and endoscopy. Disease behavior was classified according to the following: B1 = non-stricturing, non-penetrating; B2 = structuring; B3 = penetrating; P = perianal disease modifier. The change in Montreal Classification is presented in three categories: no change, deterioration, and improvement. Deterioration was defined as an increase in behavior index between 1 and 3, or development of perianal disease. Participants with missing data at Week 48 were classified as deterioration.

Time frame:
From Baseline to 48 weeks after Randomization
Reported as:
Count of participants · Participants
Change in Crohn's Disease Behavior According to Montreal Classification
ParticipantsClinically Driven ManagementTight Control Management
Deterioration5435
No Change6479
Improvement48
SecondaryChange From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Over Time

High sensitivity C-reactive protein was analyzed by a central laboratory.

Time frame:
Baseline and 8 weeks during the prednisone run-in, and 11, 23, 35, and 48 weeks after Randomization.
Reported as:
Mean · mg/L
Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Over Time
mg/LClinically Driven ManagementTight Control Management
Week 8 of Prednisone Run-in-10.3 ± 40.04-9.2 ± 33.67
11 Weeks After Randomization-14.6 ± 31.87-15.9 ± 26.38
23 Weeks After Randomization-15.1 ± 31.59-14.7 ± 28.94
35 Weeks After Randomization-11.0 ± 31.22-14.0 ± 28.85
48 Weeks After Randomization-12.3 ± 28.97-13.2 ± 28.93
SecondaryChange in Fecal Calprotectin From Baseline to 48 Weeks After Randomization

Stool samples were analyzed by a central laboratory for fecal calprotectin qualitative measurement (\< 250 or ≥ 250 μg/g). Results are reported for participants in each category at Baseline and 48 weeks after Randomization. Participants with missing data 48 weeks after Randomization were counted as having fecal calprotectin ≥ 250µg/g.

Time frame:
Baseline and 48 weeks after Randomization
Reported as:
Count of participants · Participants
Change in Fecal Calprotectin From Baseline to 48 Weeks After Randomization
ParticipantsClinically Driven ManagementTight Control Management
Baseline < 250µg/g and Week 48 < 250µg/g814
Baseline < 250µg/g and Week 48 ≥ 250µg/g910
Baseline ≥ 250µg/g and Week 48 < 250µg/g3744
Baseline ≥ 250µg/g and Week 48 ≥ 250µg/g6852
SecondaryTotal Dose of Prednisone

The total dose of prednisone each participant received during both the run-in phase and post-randomization treatment phase.

Time frame:
From Baseline through 48 weeks after Randomization
Reported as:
Mean · mg
Total Dose of Prednisone
mgClinically Driven ManagementTight Control Management
Total Dose of Prednisone1505.7 ± 1029.831369.8 ± 1137.65
SecondaryChange From Baseline in Quality of Life in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

The IBDQ measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease, feeling in general, and mood. Each question is answered on a scale from 1 (all of the time) to 7 ( none of the time); the total score ranges from 7 (worst) to 224 (best). A positive change from baseline indicates improvement.

Time frame:
Baseline and 48 weeks after Randomization
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
units on a scaleClinically Driven ManagementTight Control Management
Change From Baseline in Quality of Life in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score31.2 ± 39.3341.9 ± 36.90
SecondaryChange From Baseline in Work Productivity Activity Index - Crohn's Disease (WPAI:CD)

The WPAI:CD questionnaire was used to assess impairments in both paid work and unpaid work due to symptoms of Crohn's Disease. The self-administered questionnaire consisted of 6 questions. Work time missed was defined as the percentage of time absent from work due to Crohn's disease in the past week. Impairment while working is the participant's assessment of the degree to which Crohn's disease affected productivity while working in the past 7 days. Total work productivity impairment takes into account both hours missed due to Crohn's disease symptoms and the patient's assessment of the degree to which Crohn's disease affected their productivity while working. Total activity impairment is the percent impairment of non-work related activities due to Crohn's disease. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.

Time frame:
Baseline and 48 weeks after Randomization
Reported as:
Mean · percent impairment
Change From Baseline in Work Productivity Activity Index - Crohn's Disease (WPAI:CD)
percent impairmentClinically Driven ManagementTight Control Management
Work time missed-12.8 ± 30.17-17.6 ± 41.33
Impairment while working-17.5 ± 23.37-25.8 ± 34.32
Overall work impairment-21.7 ± 29.68-29.2 ± 39.53
Activity impairment-19.2 ± 27.16-27.7 ± 33.22
SecondaryChange From Baseline in Patient Health Questionnaire - 9 (PHQ9)

The PHQ-9 is a 9-item questionnaire for assessing the severity of depression. Each question is answered on a scale from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 27, where higher scores indicate more severe depression. A negative change from Baseline score indicates improvement.

Time frame:
Baseline and 48 weeks after Randomization
Reported as:
Mean · units on a scale
Change From Baseline in Patient Health Questionnaire - 9 (PHQ9)
units on a scaleClinically Driven ManagementTight Control Management
Change From Baseline in Patient Health Questionnaire - 9 (PHQ9)-3.6 ± 5.65-5.6 ± 5.95
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score

The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, from 0 (not at all) to 4 (very much). The FACIT-Fatigue score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from Baseline score indicates an improvement. .

Time frame:
Baseline and 48 weeks after Randomization
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score
units on a scaleClinically Driven ManagementTight Control Management
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score7.6 ± 10.8513.0 ± 13.19
SecondaryChange From Baseline in Short-Form 36 (SF-36) Physical Component Summary and Mental Component Summary Scores

The Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2 is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary (PCS) score summarizes the subscales physical functioning, role-physical, bodily pain, and general health. The mental component summary (MCS) score summarizes the subscales vitality, social functioning, role-emotional, and mental health. Each score ranges from 0 to 100 where higher scores indicate a better quality of life. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and 48 weeks after Randomization
Reported as:
Mean · units on a scale
Change From Baseline in Short-Form 36 (SF-36) Physical Component Summary and Mental Component Summary Scores
units on a scaleClinically Driven ManagementTight Control Management
Physical Component Summary Score6.3 ± 8.349.2 ± 10.22
Mental Component Summary Score5.8 ± 12.249.3 ± 12.40

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from randomization until 70 days after the last dose of study drug (up to 58 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Clinically Driven Management—25/122 (20.5%)78/122 (63.9%)
Tight Control Management—22/122 (18%)76/122 (62.3%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventClinically Driven ManagementTight Control Management
CROHN'S DISEASEGastrointestinal disorders12/1226/122
ANAL ABSCESSInfections and infestations4/1220/122
ABDOMINAL PAINGastrointestinal disorders2/1222/122
ILEAL STENOSISGastrointestinal disorders0/1222/122
ABDOMINAL ABSCESSInfections and infestations0/1222/122
CLOSTRIDIUM DIFFICILE INFECTIONInfections and infestations0/1222/122
C-REACTIVE PROTEIN INCREASEDInvestigations2/1220/122
ABDOMINAL DISTENSIONGastrointestinal disorders1/1220/122
ABDOMINAL PAIN UPPERGastrointestinal disorders0/1221/122
ANAL FISTULAGastrointestinal disorders1/1220/122
Most frequent other events
Showing 10 of 20
Most frequent other events
EventClinically Driven ManagementTight Control Management
CROHN'S DISEASEGastrointestinal disorders23/12211/122
NAUSEAGastrointestinal disorders7/12221/122
ARTHRALGIAMusculoskeletal and connective tissue disorders19/12217/122
NASOPHARYNGITISInfections and infestations18/12218/122
HEADACHENervous system disorders15/12218/122
ABDOMINAL PAINGastrointestinal disorders15/12213/122
VOMITINGGastrointestinal disorders4/12213/122
PYREXIAGeneral disorders12/1229/122
FATIGUEGeneral disorders11/12211/122
DIARRHOEAGastrointestinal disorders2/12210/122

Baseline characteristics

Age, Continuous
Age, Continuous(years)Clinically Driven ManagementTight Control ManagementTotal
Mean31.10 ± 11.4032.10 ± 11.9731.60 ± 11.67
Age, Customized
Age, Customized(Participants)Clinically Driven ManagementTight Control ManagementTotal
< 40 years9796193
40 to < 65 years232447
≥ 65 years224
Sex: Female, Male
Sex: Female, Male(Participants)Clinically Driven ManagementTight Control ManagementTotal
Female6972141
Male5350103
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Clinically Driven ManagementTight Control ManagementTotal
White113113226
Black235
Asian325
American Indian/Alaska Native000
Native Hawaiian or other Pacific Islander000
Multi-race112
Other336
Weight
Weight(Participants)Clinically Driven ManagementTight Control ManagementTotal
< 70 kg7981160
≥ 70 kg434184
Current Tobacco Use
Current Tobacco Use(Participants)Clinically Driven ManagementTight Control ManagementTotal
Yes333164
No8991180
Disease Duration
Disease Duration(Participants)Clinically Driven ManagementTight Control ManagementTotal
≤ 2 years106106212
> 2 years161632
Crohn's Disease Endoscopy Index of Severity (CDEIS)
Crohn's Disease Endoscopy Index of Severity (CDEIS)(units on a scale)Clinically Driven ManagementTight Control ManagementTotal
Mean14.26 ± 6.92513.38 ± 6.04913.82 ± 6.503

1 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Lakatos PL, Kaplan GG, Bressler B, Khanna R, Targownik L, Jones J, Rahal Y, McHugh K, Panaccione R. Cost-Effectiveness of Tight Control for Crohn's Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective. J Can Assoc Gastroenterol. 2022 Mar 10;5(4):169-176. doi: 10.1093/jcag/gwac001. eCollection 2022 Aug. PubMed 35919766 ↗
  • Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Prymak O, Goldis A, Travis SP, Hebuterne X, Ferrante M, Rogler G, Fumery M, Danese S, Rydzewska G, Pariente B, Hertervig E, Stanciu C, Serrero M, Diculescu M, Peyrin-Biroulet L, Laharie D, Wright JP, Gomollon F, Gubonina I, Schreiber S, Motoya S, Hellstrom PM, Halfvarson J, Butler JW, Petersson J, Petralia F, Colombel JF. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. Gastroenterology. 2020 Jul;159(1):139-147. doi: 10.1053/j.gastro.2020.03.039. Epub 2020 Mar 26. PubMed 32224129 ↗
  • Panaccione R, Colombel JF, Travis SPL, Bossuyt P, Baert F, Vanasek T, Danalioglu A, Novacek G, Armuzzi A, Reinisch W, Johnson S, Buessing M, Neimark E, Petersson J, Lee WJ, D'Haens GR. Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. Gut. 2020 Apr;69(4):658-664. doi: 10.1136/gutjnl-2019-318256. Epub 2019 Jul 8. PubMed 31285357 ↗
  • Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vanasek T, Danalioglu A, Novacek G, Armuzzi A, Hebuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017 Dec 23;390(10114):2779-2789. doi: 10.1016/S0140-6736(17)32641-7. Epub 2017 Oct 31. Erratum In: Lancet. 2018 Dec 23;390(10114):2768. doi: 10.1016/S0140-6736(17)32909-4. PubMed 29096949 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2011 to primary completion in Nov 2016, 68 months.

Results were first posted in Dec 2017, 1 year 1 month after primary completion.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 68 months is above that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2010
First posted
Nov 5, 2010
StartActual
Feb 11, 2011
Primary completionActual
Nov 3, 2016
CompletionActual
Jan 3, 2017
Results first posted
Dec 7, 2017
Last update
Jan 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01235689
Responsible party
Sponsor
First posted
Nov 5, 2010
Start date
Feb 11, 2011
Primary completion
Nov 3, 2016
Completion
Jan 3, 2017
Results posted
Dec 7, 2017
Last update
Jan 16, 2018

Study contacts

Anne Robinson, Pharm.D.
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adalimumab · Prednisone · Azathioprine

Start the discussion